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Abstract 
Enhancement of cAMP degradation by increased cGMP-inhibited cAMP phosphodiesterase (cGI-PDE) activity is thought o be an 
important component of the mechanism whereby insulin counteracts catecholamine-induced lipolysis in adipocytes. In this study the 
selective cGI-PDE inhibitor OPC3911 was used to evaluate this role of cGI-PDE activation in intact rat adipocytes with special reference 
to changes in cAMP levels measured as cAMP-dependent protein kinase (cAMP-PK) activity ratios. OPC3911 completely blocked 
(IC50 = 0.3 /xM) the maximal inhibitory effect of insulin on noradrenaline-induced lipolysis and the net dephosphorylation f 
hormone-sensitive lipase and other intracellular target proteins for insulin action, whereas insulin-induced lipogenesis was not changed. 
The effect of OPC3911 on cAMP-PK activity ratios at different levels of lipolysis achieved by noradrenaline stimulation revealed that the 
reduction of cAMP-PK caused by 1 nM insulin was completely blocked by 3 /~M OPC3911. The effect of OPC3911 was not due to an 
excessive increase in cellular cAMP resulting in 'supramaximal' lipolysis unresponsive to insulin. These data demonstrate hat reduction 
in cAMP levels by the activation of cGI-PDE may be sufficient o account for the antilipolytic action of insulin. 
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I. Introduction 
Inhibition of catecholamine-induced lipolysis in adipose 
tissue is an important acute physiological effect of insulin, 
the mechanism of which is still only partly known. The 
Abbreviations: ADA, adenosine deaminase; cAMP-PK, cyclic AMP- 
dependent protein kinase; BSA, bovine serum albumin; cAMP-PDE, 
cyclic AMP-specific phosphodiesterase; cGI-PDE, cyclic GMP-inhibited 
cAMP phosphodiesterase; cilostamide, N-cyclohexyl-N-methyl-4-(1,2-di- 
hydro-2-oxo-6-quinolyloxy)butyramide, (OPC3689); dimethyl POPOP, 
1,4-bis(4-methyl-5-phenyl-2-oxazolyl)benzene; H p s, 4-(2-hydroxy- 
ethyl)-l-piperazinepropanesulfonic acid; HSL, hormone-sensitive lipase; 
OPC3911, N-cyclohexyl-N-(2-hydroxyethyl)-4-[6(1,2-dihydro-2- 
oxoquinolyloxy)]butyramide; PCV, packed cell volume; PIA, ( - ) -N 6- 
(R-phenylisopropyl)-adenosine; F'PO, 2,5-diphenyloxazole; Ro 20-1724, 
4-(3-butoxy-4-methoxybenzyl)-2-ilmidazolidone; SDS-PAGE, sodium do- 
decyl sulfate polyacrylamide g l electrophoresis. 
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activity of the rate-controlling enzyme in lipolysis, hor- 
mone-sensitive lipase (HSL), is increased by cAMP-depen- 
dent protein kinase (cAMP-PK)-catalyzed phosphorylation 
of serine-572 [1]. The antilipolytic action of insulin is 
mediated via a reduction in the rate of HSL phosphoryla- 
tion [2], at least when lipolysis has been submaximally 
stimulated with catecholamines. This is due to decreased 
cAMP-PK activity, rather than increased dephosphoryla- 
tion of HSL [3-7]. Since adipocyte cAMP-PK activity 
reflects cellular cAMP content [8], the mechanisms through 
which insulin reduces cAMP become critical determinants 
of its antilipolytic effect. Although it has been suggested 
that insulin decreases cyclic AMP synthesis through inhibi- 
tion of adenylate cyclase [9-11], this has not been a 
consistent finding [12-14]. On the other hand, Corbin et 
al. [5] have demonstrated the importance of cAMP degra- 
dation in insulin action using hydrolyzable and non-hydro- 
lyzable cAMP analogues. Insulin stimulation of the 
cGMP-inhibited cAMP phosphodiesterase (cGI-PDE) ac- 
tivity in adipocytes is well established [15-18]. The cGI- 
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PDE is serine phosphorylated and activated by insulin 
treatment of intact adipocytes [19] catalyzed by an insulin- 
stimulated cytoplasmatic serine kinase [20,21]. fl-adren- 
ergic agonists also induce phosphorylation a d activation 
of cGI-PDE, through the action of cAMP-PK, and thereby 
provide a negative feedback loop, perhaps to protect he 
cell from excessive increases in cAMP [19]. cGI-PDE has 
been shown to be phosphorylated in vitro by cAMP-PK on 
serine-427 in its putative regulatory domain [22], whereas 
the site phosphorylated in response to insulin is not yet 
known. Insulin causes ynergistic phosphorylation [23] and 
activation [24] of cGI-PDE in the presence of isoprenaline 
which indicates different phosphorylation sites. 
Numerous selective inhibitors of different types of 
PDE's have been developed [25]. Cilostamide and its 
derivative OPC3911 selectively inhibit cGI-PDE's includ- 
ing that found in adipocytes [26]. Cilostamide [27,28] or 
OPC3911 [29] have been shown to block the antilipolytic 
effect of insulin in adipocytes, which has been proposed to 
show the critical role of the cGI-PDE in this action of 
insulin. However, an obvious objection to this interpreta- 
tion has been the possibility that cGI-PDE inhibition in 
those experiments prevented cAMP degradation resulting 
in an excessive accumulation of cAMP, causing a supra- 
maximally stimulated cAMP-PK and an insulin-insensitive 
condition [6]. To rule out this possibility, we have carried 
out an extended study of the effects of cGI-PDE inhbition 
by OPC3911 on insulin-induced antilipolysis and cAMP- 
PK activity ratios. The results demonstrate hat selective 
cGI-PDE inhibition blocks the antilipolytic action of in- 
sulin and that this occurs under conditions when the 
adipocytes are insulin-sensitive. Thus, cGI-PDE does in- 
deed appear to be a key link in the antilipolytic action of 
insulin. 
2. Materials and methods 
2.1. Materials 
[32 P]orthophosphate was obtained from Amersham, Lit- 
tle Chalfont, UK; D-[3-3H]glucose was from New England 
Nuclear, Boston, MA, USA; collagenase, type 1, was from 
Worthington, Freehold, N J, USA; bovine serum albumin 
(BSA), fraction V was purchased from Sigma, St Louis, 
MO, USA and defatted [30]; porcine monocomponent and 
human recombinant insulin were gifts from Novo Nordisk, 
Copenhagen, Denmark; phenylisopropyladenosine, ad no- 
sine deaminase and adenosine were obtained from 
Boehringer-Mannheim, Germany; Kemptide, noradrenaline 
and propranolol were from Sigma. Hepes (ultra-pure) was 
supplied by Schwarz/Mann, Cleveland, OH, USA; 
OPC3911 and Cilostamide were generously supplied by Dr 
H. Hidaka, Nagoya University, Japan; Ro 20-1724 was 
kindly provided by Dr M. Lin, NIH, Bethesda, MD, USA. 
2.2. Preparation and incubation of adipocytes 
Male Sprague-Dawley rats (ALAB, Stockholm, Swe- 
den), 35-37 days old were maintained in a 12 h light-dark 
cycle for 3 days with free access to EWOS-ALAB R3 
standard lab chow and tap water, fasted overnight, and 
killed by cervical dislocation between 09.00 and 10.00 h. 
Epididymal adipose tissue was excised, chopped into small 
pieces, and incubated in Krebs-Ringer solution containing 
1.2 mM phosphate supplemented with 3.5% bovine serum 
albumin, 200 nM adenosine, 25 mM Hepes, 2 mM glu- 
cose, and 1 mg/ml collagenase, on a shaking water bath 
for 40-60 min according to a modification [31] of the 
Rodbell method [32]. The digested tissue was filtered and 
the isolated cells washed [33]. All cell media were supple- 
mented with 200 nM adenosine. The packed cell volume 
(PCV) was determined [34] and the cells stored as a 5% 
suspension in Krebs-Ringer solution with 25 mM Hepes, 
1% BSA and 2 mM glucose on a shaking bath at 37 ° C for 
3 h. Immediately before each experiment, 100 nM 
phenylisopropyladenosine (PIA) and 0.5 U/ml adenosine 
deaminase (ADA) were added to the cell suspension. 
2.3. pH-stat titration of free fatty acid release 
Rates of lipolysis were measured by titration of free 
fatty acid release from a 2% (v/v)  suspension of isolated 
adipocytes in Krebs-Ringer buffer without Hepes and with 
3.5% (w/v)  BSA, using an automatic pH-stat titration 
equipment (Mettler, Zurich, Switzerland) [35]. 
2.4. Assay of glycerol release 
Cells were incubated in Krebs-Ringer solution with 25 
mM Hepes and 3.5% bovine serum albumin as 1 ml 2% 
suspension i  the presence of hormones and effectors. The 
cells were removed by rapid centrifugation through di- 
nonyl phthalate in a Beckman Microfuge B centrifuge and 
glycerol concentration i the medium was determined in 
triplicate by a spectrophotometric method [36]. 
2.5. Determination of lipogenesis 
Three hours after the preparation of isolated adipocytes, 
1 ml of a 2% adipocyte suspension in Krebs-Ringer 
solution with 25 mM Hepes, 3.5% BSA and 0.2 /.~Ci/ml 
D-[3-3H]glucose, final concentration 0.55 mM, was incu- 
bated with the appropriate hormones/effectors in cintilla- 
tion vials on a shaking water bath at 37 ° C for 30 min. The 
incubations were terminated by the addition of 8 ml of a 
toluol-based scintillation cocktail containing 0.3 mg/ml 
dimethyl POPOP and 5 mg/ml PPO [37]. The results were 
expressed as the percentage of the added radioactivity that 
was obtained in the lipids in the toluol phase. 
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2.6. Determination of cAMP-PK activity ratios 
Adipocyte incubations were terminated 5 min after the 
addition of hormone(s) by homogenization f 800 /xl cell 
suspension (2.5%, v/v)  in 200 /zl ice-cold 50 mM Tris- 
HCI (pH 7.4), containing 50 mM EDTA, 0.5 mM OPC3911 
and 0.5 mM Ro 20-1724. The samples were immediately 
centrifuged at 14000 × g for 15 min at + 4 ° C to obtain 
supernatant fractions [31] !in which the cAMP-PK activity 
ratios were assayed under conditions previously described 
[38] using Kemptide as a specific substrate. In cells that 
were not previously incubated with cilostamide, cilostamide 
at 0.3-3 mM had no effect on cAMP-PK activity in 
control supernatants prepared from basal or noradrenaline- 
stimulated cells. 
2. 7. Assays of enzyme activities 
Low K m cAMP-PDE activity was assayed by a modifi- 
cation of a previously described procedure [16]. Samples 
were incubated at 30 ° C, usually for 8 min, in a total 
volume of 0.3 ml containing 50 mM Hepes (pH 7.40), 0.1 
mM EDTA, 8.3 mM MgC12, 0.5 mM [3H]cAMP (15 000 
cpm). Under these conditions cAMP-PDE activity was 
proportional to enzyme concentration a d substrate hydrol- 
ysis was less than 20%. cGI-PDE activity was estimated as 
the fraction inhibited by 3 /xM OPC3911 and 1 /zM 
cGMP [26]. 
2.8. In vivo 32p-phosphorylation of adipocyte proteins 
Cells (2% v /v  suspension) were labelled with 0.1 
mCi/ml [32p]p in fresh medium modified to contain 600 
/zM phosphate and 3.5% BSA for 1 h at 37°C to obtain 
steady-state specific activity of intracellular [32 P]ATP [39]. 
One milliliter samples were transferred to scintillation 
vials containing the appropriate hormones and effectors. 
After 10 min, samples (250 /xl) of the cell suspension 
were rapidly ( < 10 s) centrifuged in a Beckman Microfuge 
B in polypropylene tubes with 100 /xl dinonyl phthalate. 
The cells floating on the dinonyl phthalate were carefully 
dissolved in 50 /xl of 8 mM sodium pyrophosphate/1.6 
mM EDTA/20 mg/ml of each of leupeptin, antipain and 
pepstatin/20% (v /v)  ethanol/0.1% fl-mercapto- 
ethanol/4% sodium dodecyl sulfate/Bromophenol blue 
and then the tubes were frozen and sliced through the 
dinonyl phthalate layer. The cell-containing top fraction 
was rapidly separated from remaining dinonyl phthalate by 
centrifugation, followed by boiling, centrifugation a d as- 
piration of the infranatant. The dinonyl phthalate phase 
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Fig. 1. Effect of OPC3911 on the antilipolytic action of insulin (A) or propranolol (B). The continous release of fatty acids from isolated rat adipocytes in
the presence of 100 nM PIA and 0.5 U/ml  ADA was measured with a pH-stat itrator. At 0 min, lipolysis was stimulated by the addition of 100 nM 
noradrenaline (incubation I, solid line, and III, dotted line) or 100 nM noradrenaline and 1 /xM OPC3911 (incubation II, hatched line). Incubation I 
received no further additions during the experiment and served as a control. Insulin (A): at 9 min, 1 nM insulin was added to incubations II and III. At 19 
min, 1 /xM OPC3911 was added to incubation III in the continued presence of insulin. Propranolol (B): at 9 min, 1 /xM propranolol was added to each of 
the incubations II and III. At 19 min, 1 p,M OPC3911 was added to incubation III in the continued presence of propranolol. The graphs depicts one 
representative experiment, where incubations II and III were performed in parallell using two pH-stat itrators, followed by incubation I.
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was extracted once more with 50 /xl of fresh SDS reagent 
solution to recover all cellular proteins. Samples (75 tzl) of 
the pooled extract were subjected to SDS-PAGE in 8% 
gels [40]. After Coomassie brilliant blue staining, the dried 
gels were autoradiographed on Amersham Betamax Hyper- 
film or Kodak X-Omat AR film. Radioactive bands were 
semi-quantified by light densitometry. 
3. Results 
3.1. Relative amounts of cAMP-PDE activities in fat cells 
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To evaluate the relative abundance in adipocytes of the 
low g m cAMP phosphodiesterases, a series of experiments 
with different PDE-inhibitors was performed. Based on 
selective inhibition by 3/zM OPC3911 [26], cGI-PDE was 
estimated to account for about 80% of the total fat cell low 
K m cAMP-PDE activity (assayed with 0.5 /xM cAMP), 
80% of which resided in the particulate fraction (50 000 
X g) of a fat cell homogenate. The cGI-PDE constituted 
practically all (> 90%) of the cAMP-PDE activity in this 
fraction and about 45% of the corresponding supernatant 
activity. Most of the non-cGI-PDE activity, which is not 
inhibited by 10/~M OPC3911 [25], was presumably due to 
the cAMP-specific PDE since the selective inhibition of 
this enzyme with 30 /xM Ro 20-1724 inactivated about 
10% of the total fat cell cAMP-PDE activity. Thus, the 
OPC3911-sensitive cGI-PDE accounts for almost all of the 
hydrolysis of low concentrations of cAMP by adipocyte 
homogenates. 
3.2. Effect of 0PC3911 inhibition of cGI-PDE on the 
anti-lipolytic effects of insulin and propranolol 
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Fig. 2. Effects of OPC3911 on the antilipolytic and lipogenic effects of 
insulin. (A) Isolated rat adipocytes were were incubated with 100 nM 
noradrenaline and 1 nM insulin and the effect of increasing concentra- 
tions of OPC3911 (O) or Ro 20-1724 (O) on the antilipolytic effect of 
insulin was determined. Values are expressed as the percent inhibition of 
the antilipolytic effect of insulin. (B) The effect of OPC3911 on basal 
lipogenesis (O)  and lipogenesis timulated with 1 nM insulin (Q)  in 
isolated rat adipocytes. Values are expressed as percent of the effect of 
insulin. Data represent means of at least three experiments analyzed in 
triplicates. 
We performed a series of experiments o illustrate that 
OPC3911 specifically blocked insulin-induced antilipolysis 
by inhibiting cGI-PDE. The lipolysis rate in isolated rat 
adipocytes was continuously monitored by measuring re- 
lease of fatty acids to the medium with a pH-stat titrator 
[35]. As described by Honnor et al. [31], cAMP-PK activ- 
ity ratio reflecting the cAMP level and lipolysis were 
maintained at a minimal basal level by including 100 nM 
phenylisopropyladenosine (PIA) and adenosine deaminase 
(ADA), 0.5 U/ml, in the incubation medium. Under these 
conditions, noradrenaline stimulated lipolysis with an EDso 
of 54 _+ 4 nM (mean _+ S.E., n = 3). Submaximal (88 +__ 
6%; mean + S.E., n = 3) stimulation of lipolysis by 100 
nM noradrenaline r sulted in a more than 50-fold increase 
of the lipolysis rate (cf. Ref. [2]), which was almost 
completely (> 90%) reversed by 1 nM insulin within 10 
min (Fig. 1A). Inhibition of the fat cell cGI-PDE by 1 /xM 
OPC3911, which caused a small enhancement of the stim- 
ulation of lipolysis by noradrenaline, inhibited the anti- 
lipolytic action of insulin by about 65%, whereas 3 /xM 
OPC3911 almost completely blocked the response to in- 
sulin (> 95%, data not shown). When added 10 min after 
insulin, at a time when the anti-lipolytic effect was maxi- 
mal, OPC3911-mediated cGI-PDE inhibition reversed most 
(1 tzM OPC3911, cf. Fig. 1A) or all (3 /xM OPC3911; 
99 _ 6% mean + SD, n = 3) of the antilipolytic action of 
insulin. In contrast o these effects, the inhibition of nor- 
adrenaline-stimulated lipolysis caused by the /3-adrenergic 
antagonist propranolol was only to a minor degree pre- 
vented or reversed by OPC3911 (Fig. 1B). 
As seen in Fig. 2A, the IC5o of the insulin-antagonistic 
effect of OPC3911 was 0.48 + 0.06 uM (mean + S.E., 
n = 9), measured as the ability to block the antilipolytic 
effect of 1 nM insulin in the presence of 100 nM nor- 
adrenaline. The antilipolytic effect of 1 nM insulin was 
essentially completely blocked (> 90%) at 3 /xM 
OPC3911. The Type IV cAMP-specific cAMP-PDE in- 
hibitor Ro 20-1724 (1-100 tzM) did not measurably affect 
the antilipolytic action of insulin (Fig. 2A). At 30 /xM, Ro 
20-1724 has been shown to inhibit completely the cAMP- 
specific AMP-PDE [22] with negligible ffect on cGI-PDE 
[26]. 
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Fig. 3. Effects of OPC3911 on adipocyte protein phosphorylation. Iso- 
lated rat adipocytes were preincubated with 100 IxCi/ml [32 Plorthophos- 
phate for 60 rain and then incubated for 10 min with vehicle (lane A); 
100 nM noradrenaline (lane B); 100 nM noradrenaline and 1 nM insulin 
(lane C); 100 nM noradrenaline, 1. nM insulin and 3 ~M OPC3911 (lane 
D); 1 nM insulin (lane E); or 3 ~M OPC3911 (lane F). Total cellular 
proteins were subjected to8% SDS-PAGE and 32 P-proteins visualized by 
autoradiography. 
As seen in Fig. 2B, neither basal nor insulin-stimulated 
(1 nM) lipogenesis was affected by OPC3911. 
3.3. Effect of 0PC3911 inhibition of cGI-PDE on insulin- 
induced net dephosphorylation f HSL 
In rat adipocytes, insulin antagonizes catecholamine-in- 
duced phosphorylation a d activation of HSL [2]. As shown 
in Fig. 3 the net dephosphorylation f HSL induced by 
insulin (lane C vs. lane 13) was completely blocked by 
inhibition of cGI-PDE with 3 uM OPC3911 (lane D vs. 
lane C). The IC50 for OPC3911 inhibition of insulin-in- 
duced HSL dephosphorylation was 0.3 /.~M (based on 
experiments using 0.1-10 /xM OPC3911) similar to the 
IC50 value of 0.48 /xM for inhibition of the antilipolytic 
action of insulin. Insulin also affects the phosphorylation 
state of several other adipocyte proteins, notably 49, 65 
and 98 kDa phosphoproteins and the prominent 121-kDa 
ATP:citrate lyase [41] (lane: B vs. lane C). cGI-PDE inhibi- 
tion by OPC3911 prevented the insulin-induced net 
dephosphorylation f the former three phosphoproteins, 
whereas it had no appreciable ffect on the increased 
phosphorylation of the 12]-kDa ATP:citrate lyase caused 
by insulin (lane C vs. lane D), which is thought to be 
mediated through a cyclic AMP-independent mechanism 
[42]. Addition of OPC3911 alone had no measurable effect 
on the phosphorylation f HSL or any of the other phos- 
phoproteins (lane F). 
3.4. Effect of OPC3911-mediated cGI-PDE inhibition on 
cAMP-PK activity ratios 
Having confirmed that insulin-induced antilipolysis can 
be blocked by cGI-PDE inhibiton in isolated adipocytes, it 
is critical to demonstrate hat this inhibition also results in 
a block of the decrease in cAMP and cAMP-PK activity 
caused by insulin. Honnor et al. [43] reported a strong 
positive relationship between the rate of lipolysis and the 
cAMP-PK activity ratio, the latter directly reflecting cellu- 
lar cAMP concentrations. Under standardised conditions, 
insulin decreased the cAMP-PK activity ratio (and presum- 
ably cAMP concentration) achieved by incubation of 
adipocytes with catecholamines alone, indicating that the 
inhibitory effect of insulin on lipolysis was also mediated 
through a cAMP-dependent mechanism. We performed a
series of experiments to determine whether inhibition of 
cGI-PDE prevented insulin from reducing cAMP as re- 
flected in cAMP-PK activity ratios in intact adipocytes. 
cAMP-PK activity ratios were measured 5 min and lipoly- 
sis 10 min after the addition of hormones and/or OPC3911. 
As previously reported by Honnor et al. [40], the rate of 
lipolysis was directly related to cAMP-PK activity ratios in 
the range of 0.1 to 0.4 (Fig. 4C). Noradrenaline induced a 
dose-dependent i crease in cAMP-PK activity ratio (Fig. 
4A) and rate of lipolysis (Fig. 4B), as expected. Insulin at 
1 nM counteracted this effect by substantially reducing 
cAMP-PK activity ratios and by decreasing lipolysis to 
basal levels, except with 1 p~M noradrenaline when lipoly- 
sis was reduced by 71%. At all concentrations of nor- 
adrenaline tested, inhibition of lipolysis induced by 1 nM 
insulin was completely reversed by 3 /xM OPC3911. As 
illustrated in Fig. 4C, these changes in lipolysis, with no 
exception, correlated irectly with changes in cAMP-PK 
ratios, strongly indicating that the effect of insulin might 
be fully explained by the activation of cGI-PDE and 
reduction in cAMP. Furthermore, OPC3911 alone pro- 
duced a small leftward shift in the concentration-depend- 
ency of the effect of noradrenaline on the cAMP-PK 
activity ratios (Fig. 4A, B). OPC3911 alone did not signifi- 
cantly change the basal cAMP-PK activity ratio. 
4. Discussion 
We have obtained further evidence supporting the no- 
tion that insulin-induced activation of the cGI-PDE may be 
sufficient to account for the antilipolytic effect of the 
hormone. Earlier experiments by us [27] and others [28,29] 
indicated that inhibition of cGI-PDE with cilostamide or 
its derivative OPC3911 blocked the antilipolytic effect of 
insulin. However, the possibility in these experiments ex- 
isted that this inhibition might have lead to excessive 
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Fig. 4. Effects of noradrenaline, insulin and OPC3911 on cAMP-PK activity ratios and lipolytic rates. Isolated rat adipocytes were incubated with 100 nM 
PIA and 0.5 U/ml ADA and then with increasing concentrations f noradrenaline i  the presence ofvehicle (O), 1 nM insulin (A), 1 nM insulin and 3 
txM OPC3911 (A), or 3 /xM OPC3911 (0). (A) cAMP-PK activity ratios were measured after 5 min and (B) lipolysis determined asthe amount of 
glycerol released uring the first 10 min of each incubation. (C) Lipolytic rates from individual experiments (irrespective ofhormonal treatment) were 
plotted as a function of cAMP-PK activity ratio (.); the sigmoidal curve was generated byleast-square analysis. Data from A and B were replotted to 
illustrate the reversal by 3 txM OPC3911 of the antilipolytic effect of 1 nM insulin (arrows) at different rates of lipolysis obtained in the presence of30, 
100 or 1000 nM noradrenaline. 
accumulation of cAMP and activation of cAMP-PK to 
levels where insulin could no longer modulate lipolysis, 
i.e., an insulin-insensitive state [6]. We demonstrate here 
that OPC3911 inhibition of cGI-PDE alone caused a small 
increase in cAMP levels, as reflected in cAMP-PK activity 
ratios, but no excessive accumulation making the cells 
insensitive to insulin action. Inhibition of cGI-PDE with 
OPC3911 clearly blocked the ability of insulin to decrease 
cAMP-PK activity ratio and inhibit lipolysis at different 
noradrenaline activation levels. The maximally inhibitory 
concentration (3 /zM) of OPC3911 also inhibited the 
insulin effect on HSL phosphorylation aswell as phospho- 
rylation of other target proteins for cAMP-PK action but 
not insulin-induced phosphorylation of ATP-citrate lyase 
believed not to be mediated by cAMP-PK. 
OPC3911, at the concentrations used in this study to 
selectively inhibit cGI-PDE, does not markedly inhibit 
other PDE activities [25]. We demonstrate that the 
OPC 3911-sensitive cGI-PDE activity in contrast o the Ro 
20-1724-sensitive Type IV cAMP-specific PDE activity is 
responsible for most of the hydrolysis of low concentra- 
tions of cAMP in adipocyte homogenates. Type IV PDE 
activity is not involved in the antilipolytic effect of insulin 
since it was not antagonized by Ro 20-1724. Similar 
differential effects of the two PDE inhibitors cilostamide 
and Ro 20-1724 on the ability of insulin to inhibit lipolysis 
have been observed in 3T3-L1 adipocytes [27] and 
adipocytes [28]. 
The lack of inhibitory effect of OPC3911 on propra- 
nolol-induced antilipolysis indicates that OPC3911 does 
not act via a direct stimulatory effect on adenylate cyclase. 
It also suggests that the effect of OPC3911 is not due to 
inhibition of HSL dephosphorylation, or to interference 
with reduction of cAMP by some other possible mecha- 
nism, e.g., compartmentalization. It is also evident hat the 
insulin-antagonistic effects of OPC3911 are not due to an 
intrinsic lipolytic action of OPC3911. 
Since OPC3911 does not alter lipogenesis, it seems 
unlikely that the interaction of insulin with its receptor is 
altered or that an activated cGI-PDE is a component of the 
signal chain from the insulin receptor to the recruitment of 
glucose transporters. This further suggests that the insulin 
signal chain must diverge at some point distal to the 
insulin receptor tyrosine kinase [44] and the PI-3 kinase 
[45,21], which have been shown to be necessary for the 
stimulation of glucose uptake, but proximal to those com- 
ponents of the molecular cascade involved in activation of 
the intracellular protein serine kinase [21] that presumably 
phosphorylates and activates the cGI-PDE. 
In summary, we have demonstrated that in intact 
H. Eriksson et al. / Biochimica et B iophysica Acta 1266 (1995) 101-107 107 
adipocytes a specific inhibitor of the cGI-PDE selectively 
prevents the antilipolytic effect of insulin by blocking 
insulin-induced changes in cAMP-PK activity ratio. We 
propose that insulin inhibition of lipolysis results from the 
phosphorylation a d actiwLtion of the cGI-PDE [17] by an 
insulin-stimulated serine kinase [21] resulting in increased 
intracellular cAMP breakdown leading to decreased 
cAMP-PK activity and subsequent et dephosphorylation 
and deactivation of HSL. Although additional mechanisms 
may be involved in certain conditions, activation of cGI- 
PDE could be sufficient o account for the antilipolytic 
effect of insulin, and perhaps for insulin regulation of other 
cAMP-mediated processes, such as hepatic glycogen 
metabolism as suggested by other workers [5,46]. 
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